The objective is to examine and further characterize the ability of antibody directed against gram-negative bacterial lipopolysaccharide (LPS, endotoxin) to afford protection during experimental gram-negative bacillary sepsis. The core LPS-lipid A portion of endotoxin represents an antigenic determinant common to many common gram-negative microorganisms. This region of LPS is expressed extensively on the cell surface of rough mutants of Escherichia coli and Salmonella minnesota. These organisms or their derived outer membrane LPS thus represent suitable immunogens for cross-reactive antibody production. Although we have demonstrated protection in vivo utilizing murine monoclonal antibodies directed against the core LPS-lipid A region, the exact binding site specificity and antibody class which will maximize protection has not been established. Thus, IgG and IgM monoclonal antibodies of similar binding specificity, and monoclonal and polyclonal preparations have not been directly compared. The major thrust of this work will be to develop and test both monoclonal and polyclonal antibody preparations which bind to different portions of LPS. Different classes of monoclonal antibodies with similar binding specificity will be developed. These antibody preparations will be tested in vitro for: 1) antibody titer (enzyme-linked immunosorbent assay), 2) binding specificity (Western blot analysis, immunofluorescent bacterial binding), and opsonophagocytic character (acridine orange slide phagocytosis assay). Initial in vivo testing will establish protective capacity by exact LD50 calculations in three murine sepsis models: 1) IV bacteremia, 2) ip hemoglobin peritonitis, and 3) iv endotoxemia. Further in vivo testing will center around maximizing the protective effect of suitable antibody preparations. The ability of antibody to promote survival as a therapeutic agent administered after the bacterial challenge, either alone or in conjunction with antimicrobial agents and the immunoenhancing agent muramyl dipeptide will be examined in the above models and a chronic peritonitis-sepsis model.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Research Project (R01)
Project #
Application #
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Minnesota Twin Cities
Schools of Medicine
United States
Zip Code
Leslie, Daniel B; Vietzen, Paul S; Lazaron, Victor et al. (2006) Comparison of endotoxin antagonism of linear and cyclized peptides derived from limulus anti-lipopolysaccharide factor. Surg Infect (Larchmt) 7:45-52
Lazaron, Victor; Dunn, David L (2002) Molecular biology of endotoxin antagonism. World J Surg 26:790-8
Lazaron, V; Leslie, D B; Wasiluk, K R et al. (2001) Accelerated internalization and detoxification of endotoxin by anti-lipopolysaccharide antibody is an Fc receptor--mediated process. Surgery 130:192-7
Kellogg, T A; Lazaron, V; Wasiluk, K R et al. (2001) Binding specificity of polymyxin B, BPI, LALF, and anti-deep core/lipid a monoclonal antibody to lipopolysaccharide partial structures. Shock 15:124-9
Weiss 3rd, C A; Wasiluk, K R; Kellogg, T A et al. (2000) Bactericidal and endotoxin neutralizing activity of a peptide derived from Limulus antilipopolysaccharide factor. Surgery 128:339-44
Kellogg, T A; Weiss 3rd, C A; Johnston, J W et al. (1999) Antiendotoxin agents share molecular homology within their lipopolysaccharide binding domains. J Surg Res 85:136-41
Klaerner, H G; Dahlberg, P S; Acton, R D et al. (1997) Immunization with antibodies that mimic LPS protects against gram negative bacterial sepsis. J Surg Res 69:249-54
Uknis, M E; Wasiluk, K R; Acton, R D et al. (1997) Design of a potent novel endotoxin antagonist. Surgery 122:380-5
Dahlberg, P S; Acton, R D; Battafarano, R J et al. (1996) A novel endotoxin antagonist attenuates tumor necrosis factor-alpha secretion. J Surg Res 63:44-8
Dahlberg, P S; Acton, R D; Uknis, M E et al. (1996) Macrophages expressing a fusion protein derived from bactericidal/permeability-increasing protein and IgG are resistant to endotoxin. Arch Surg 131:1173-7;discussion 1177-8

Showing the most recent 10 out of 26 publications